ZYXI
Zynex·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 3
High Gross Profit Margin
Significant Net Income Decline
Low Beta
EPS Below Expectations
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ZYXI
Zynex Inc.
An innovative medical technology company that specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring
Healthcare Equipment and Supplies
--
02/12/2019
NASDAQ Stock Exchange
1,000
12-31
Common stock
9555 Maroon Cir, Englewood, CO 80112
--
Zynex Inc., through its subsidiaries, sells electrotherapy products that help improve the lives of people with functional disabilities. The company's products include muscle stimulation, reasoning and TENS devices. Zynex products are primarily used for stroke rehabilitation, spinal cord injury rehabilitation, incontinence and other applications.
Earnings Call
Q1/2025
Estimate EPS-0.24
Actual EPS-0.33
Estimate Revenue30.75M
Actual Revenue26.58M
Zynex's 2025 Outlook: Contradictions in TriCare Payments, Revenue Guidance, and NiCo Launch Strategy
May 02,2025 07:28
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.2
Actual EPS-0.66
Estimate Revenue27.38M
Actual Revenue22.30M
Zynex's Q2 2025 Earnings Call: Unpacking Contradictions in TRICARE Revenue, Cost Management, and FDA Approvals
Aug 01,2025 08:08
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
ZYXI has released its 2025 Q3 earnings. EPS was reported at -1.42, versus the expected -0.13, missing expectations. The chart below visualizes how ZYXI has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ZYXI has released its 2025 Q3 earnings report, with revenue of 13.36M, reflecting a YoY change of -73.26%, and net profit of -42.91M, showing a YoY change of -1901.60%. The Sankey diagram below clearly presents ZYXI's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
